486 related articles for article (PubMed ID: 36109798)
1. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
[TBL] [Abstract][Full Text] [Related]
2. An epidemiological and clinicopathological study of type 1 vs. type 2 morphological subtypes of papillary renal cell carcinoma- results from a nation-wide study covering 50 years in Iceland.
Runarsson TG; Bergmann A; Erlingsdottir G; Petursdottir V; Heitmann LA; Johannesson A; Asbjornsson V; Axelsson T; Hilmarsson R; Gudbjartsson T
BMC Urol; 2024 May; 24(1):105. PubMed ID: 38741053
[TBL] [Abstract][Full Text] [Related]
3. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
[TBL] [Abstract][Full Text] [Related]
4.
Klümper N; Ralser DJ; Zarbl R; Schlack K; Schrader AJ; Rehlinghaus M; Hoffmann MJ; Niegisch G; Uhlig A; Trojan L; Steinestel J; Steinestel K; Wirtz RM; Sikic D; Eckstein M; Kristiansen G; Toma M; Hölzel M; Ritter M; Strieth S; Ellinger J; Dietrich D
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446578
[TBL] [Abstract][Full Text] [Related]
5. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications.
Linehan WM; Ricketts CJ
Nat Rev Urol; 2019 Sep; 16(9):539-552. PubMed ID: 31278395
[TBL] [Abstract][Full Text] [Related]
6. A pan-kidney cancer study identifies subtype specific perturbations on pathways with potential drivers in renal cell carcinoma.
Zhan X; Liu Y; Yu CY; Wang TF; Zhang J; Ni D; Huang K
BMC Med Genomics; 2020 Dec; 13(Suppl 11):190. PubMed ID: 33371886
[TBL] [Abstract][Full Text] [Related]
7. PRMT1 expression in renal cell tumors- application in differential diagnosis and prognostic relevance.
Filipović J; Bosić M; Ćirović S; Životić M; Dunđerović D; Đorđević D; Živković-Perišić S; Lipkovski A; Marković-Lipkovski J
Diagn Pathol; 2019 Oct; 14(1):120. PubMed ID: 31655611
[TBL] [Abstract][Full Text] [Related]
8. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
9. Association between PD-L1 Expression and the Prognosis and Clinicopathologic Features of Non-Clear Cell Renal Cell Carcinoma.
Chrabańska M; Szweda-Gandor N; Rynkiewicz M; Hraboš D; Drozdzowska B
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612724
[TBL] [Abstract][Full Text] [Related]
10. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium.
Abu-Ghanem Y; Powles T; Capitanio U; Beisland C; Järvinen P; Stewart GD; Gudmundsson EO; Lam TB; Marconi L; Fernandéz-Pello S; Nisen H; Meijer RP; Volpe A; Ljungberg B; Klatte T; Dabestani S; Bex A
Eur Urol Oncol; 2021 Jun; 4(3):473-482. PubMed ID: 33109495
[TBL] [Abstract][Full Text] [Related]
12. Identification of molecular subtypes based on chromatin regulator and tumor microenvironment infiltration characterization in papillary renal cell carcinoma.
Tang Q; Pan D; Xu C; Chen L
J Cancer Res Clin Oncol; 2023 Jan; 149(1):231-245. PubMed ID: 36404389
[TBL] [Abstract][Full Text] [Related]
13. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.
Waldert M; Haitel A; Marberger M; Katzenbeisser D; Ozsoy M; Stadler E; Remzi M
BJU Int; 2008 Nov; 102(10):1381-4. PubMed ID: 18782311
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.
Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK
Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
Choueiri TK; Plantade A; Elson P; Negrier S; Ravaud A; Oudard S; Zhou M; Rini BI; Bukowski RM; Escudier B
J Clin Oncol; 2008 Jan; 26(1):127-31. PubMed ID: 18165647
[TBL] [Abstract][Full Text] [Related]
16. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles.
Govindarajan A; Salgia NJ; Li H; Castro DV; Mirzapoiazova T; Armstrong B; Zhao D; Mercier BD; Dizman N; Chawla N; Zengin Z; Meza L; Tripathi N; Sayegh N; Chehrazi-Raffle A; Tripathi A; Pal SK
Front Immunol; 2023; 14():1182581. PubMed ID: 37638025
[TBL] [Abstract][Full Text] [Related]
17. Dyskerin and telomerase RNA component are sex-differentially associated with outcomes and Sunitinib response in patients with clear cell renal cell carcinoma.
Yuan H; Qin X; Yang Q; Liu L; Fang Z; Fan Y; Xu D
Biol Sex Differ; 2023 Jul; 14(1):46. PubMed ID: 37434223
[TBL] [Abstract][Full Text] [Related]
18. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
19. 2018 Leibovich prognostic model for renal cell carcinoma: Performance in a large population with special consideration of Black race.
Schmeusser BN; Patil DH; Nicaise EH; Armas-Phan M; Nabavizadeh R; Narayan VM; Joshi SS; Ogan K; Osunkoya AO; Bilen MA; Master VA
Cancer; 2024 Feb; 130(3):453-466. PubMed ID: 37803521
[TBL] [Abstract][Full Text] [Related]
20. A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy.
Lin J; Cai Y; Ma Y; Pan J; Wang Z; Zhang J; Liu Y; Zhao Z
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
